



Universiteit
Leiden
The Netherlands

Circulating non-coding RNAs in kidney disease

Zhao Q.

Citation

Circulating non-coding RNAs in kidney disease. (2025, December 16). *Circulating non-coding RNAs in kidney disease*. Retrieved from <https://hdl.handle.net/1887/4285268>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4285268>

Note: To cite this publication please use the final published version (if applicable).

STELLINGEN

behorende bij het proefschrift

CIRCULATING NON-CODING RNAs IN KIDNEY DISEASE

1. Although early studies typically focused on total levels of circulating ncRNAs, it is now clear that ncRNAs can be transported in the circulation in a diverse array of carriers that can demonstrate carrier-specific targeting mechanisms. *This thesis*
2. Circulating angiogenic miRNAs, Ang-2 and ADMA have the potential to serve as biomarkers for cardiovascular structure and function in older patients reaching end stage kidney disease. *This thesis*
3. Silencing MALAT1 reduced fibrosis by preserving vascular integrity, suggesting that therapies targeting MALAT1 in the vasculature may offer a potential treatment for chronic kidney disease. *This thesis*
4. RNYs are sensitive and specific enough to potentially serve as biomarkers for the diagnosis of diabetic kidney disease. *This thesis*
5. The role of RNYs in endothelial damage may be significant for understanding the pathogenesis and treatment of diabetic kidney disease. *This thesis*
6. Assessment of Y-RNA-subtype ratios could be useful in diagnosis of inflammatory diseases. *This thesis and Driedonks et al. J Extracell Vesicles. 2020*
7. Further advances in lncRNA-targeted drugs are clearly dependent on the in-depth basic research into the function and mechanisms of lncRNAs. *Chen et al. Acta pharmaceutica Sinica. 2021*
8. Improvements in (small) RNA-seq protocols are necessary to accurately detect small RNA levels and its modifications. *Bai et al. Genes Dis. 2024*
9. In the rapidly evolving field of miRNA delivery techniques, combinations of different strategies should be tested to further enhance the therapeutic effectiveness and specificity of the cellular targeting. *Diener et al. Trends in Genetics. 2022*
10. The complexity of non-coding RNAs regulatory network turns research into a detective story. To identify the true culprit, remember being bold in making a hypothesis, but careful in proving it. *This thesis and Hu Shi*
11. The expression levels of non-coding RNAs do not change for no reason, as nature does nothing in vain. *This thesis and Aristotle*